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CYTOTOXIC ACTIVITY OF METFORMIN in vitro dOES NOT 
CORRELATE WITH ITS ANTITUMOR ACTION in vivo
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R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology,  
NAS of Ukraine, Kyiv 03022, Ukraine
It is known that metformin is a hypoglycemic drug used to treat type II diabetes mellitus. Recently active studies of its antitumor 
activity in relation to different types of malignant cells are conducted. Aim: To determine the relationship between cytotoxic activity 
of metformin in vitro and its antitumor activity in vivo. Materials and Methods: The rat C6 glioma cell line and mouse Lewis lung 
carcinoma cells (LLC) were used in this work. The number of living cells in the cytotoxic test was evaluated using sulforhodamine B. 
Parameters of tumor cell susceptibility to metformin activity in vitro were calculated using nonlinear and linear regression of experi-
mental data. The antitumor action of metformin in vivo was evaluated routinely by the extension of survival time (ST) (in rats with 
intracerebral C6 glioma) and its effect on the volume of the primary tumor, the number and volume of metastases (in mice with LLC). 
Results: In cultured LLC cells in vitro, the proportions of metformin-resistant (A1, %) and metformin-sensitive (A2, %) subpopulations 
were 10.0 ± 2.2% and 92.0 ± 3.5%, respectively, in terms of the total number of living cells. Parameter t, which characterizes the 
sensitivity of cancer cells to metformin action (the lower is the value of this parameter the higher is sensitivity of cells to metformin 
cytotoxicity), for metformin-resistant and metformin-sensitive subpopulations was: t1(mM) = ∞ and t2(mM) = 2.9 ± 0.3, cor-
respondingly. For metformin-sensitive subpopulation of LLC cells IC50 (mM) = 2.42 ± 0.34. The volume of the primary tumor, 
the amount and volume of metastases in mice receiving metformin at a dose of Dmin (0.15 g/kg) and Dmax (0.3 g/kg) values did 
not significantly differ from those in the control. However, in the case of Dmin, there was a tendency to increased volume of the 
primary tumor, in the case of Dmax, there was a tendency to increased volume of metastases. The analogical parameters (A1, A2, 
b1, b2, IC50 (1), IC50 (2)) characterizing cell sensitivity to the action of metformin in vitro were obtained in relation to C6 glioma 
cells. In metformin-resistant subpopulation, these parameters were: A1 (%) = 72.3 ± 1.4; b1 (%/mM) = 0.43 ± 0.005; IC50 (1) 
(mM) = 84.1 ± 2.4. For metformin-sensitive subpopulation, these parameters were: A2 (%) = 30.8 ± 2.3; b2 (%/mM) = 2.87 ± 0.4; 
IC50 (2) (mM) = 5.37 ± 0.45. In vivo, a statistically significant anti-glioma effect of metformin was observed: at a dose of Dmax 
(5.2 g/kg) administration of this preparation resulted in a prolongation of the mean ST of tumor-bearing rats by 23% (p < 0.05) 
compared with that in the control. Conclusions: We found no correlation between the cytotoxic/cytostatic action of metformin 
in vitro and its antitumor activity in vivo on the two types of tumor cells; these results indicate a significant contribution of the 
tumor microenvironment to the implementation of the antitumor activity of the drug.
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Presently, metformin, which has long been known 
as an effective hypoglycemic agent for the treatment 
of type II diabetes mellitus, is being investigated 
as a potential antitumor agent. This drug has attracted 
the attention of oncologists due to clinical observations 
regarding the reduction in the cancer incidence and 
cancer-related death rate in diabetic patients treated 
with metformin [1]. Today, the ability of metformin 
to suppress the growth of various types of malignant 
cells has been confirmed in many in vitro and in vivo 
studies [2–6].
It is believed that the basis of antitumor activity 
of metformin lies in its ability to moderately inhibit 
NADH: ubiquinone-oxidoreductase of mitochondria 
or complex I of the electron transport chain. Com-
plex I plays a key role in the processes of cellular 
respiration and oxidative phosphorylation and pro-
vides almost 40% of the total proton gradient for the 
synthesis of ATP in cells [7]. Inhibition of complex I with 
metformin leads to an increase in the AMP/ADP ratio 
in the cell and, accordingly, to the activation of the 
AMP-activated protein kinase (AMPK), main controller 
of energy metabolism [8–10]. In addition to activating 
the AMPK pathway, the down regulation of the mTOR 
signaling, which is critical for the survival and prolife-
ration of tumor cells [9, 11], and AMPK-independent 
mechanisms [12, 13] are included in the antitumor 
pathways affected by metformin. However, the anti-
tumor properties of metformin, persuasive in vitro, are 
not so rosy in the clinical situation. Although clinical 
trials of metformin for cancer therapy, in particular 
breast cancer treatment, are ongoing, there are ques-
tions about the effective doses of the drug, the range 
of tumors that are sensitive to its action, the exact 
mechanisms of its effects, there is a need for biomark-
ers of tumor sensitivity to this preparation, etc. [14, 15].
The aim of this work was to determine the relation-
ship between in vitro cytotoxic action of metformin and 
its antitumor activity in vivo. As an experimental tumor 
models, we used the Lewis lung carcinoma (LLC) and 
rat C6 glioma cells.
MATERIALS ANd METHOdS
Experimental animals and tumor mo dels. The 
study was performed in female Wistar rats 2.5–3 months 
old weighting 100–130 g, and С57BL/6 mice 
2–2.5 months old weighting 18–22 g bred at animal 
facility of R.E. Kavetsky Institute of Experimental Pa-
thology, Oncology and Radiobio logy of the National 
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Academy of Sciences of Ukraine (IEPOR), Kyiv, Ukraine. 
The use and care of the experimental animals was per-
formed in accordance with the standard international 
rules of biologic ethics and was approved by Institutional 
Animal Care and Use Committee.
Glioma С6 cell line and LLC cells were obtained 
from the National Bank of Cell Lines and Tumor Strains 
of IEPOR. Both tumor cells types were maintained 
in vitro in DMEM (C6 glioma) and RPMI 1640 (LLC) 
culture medium (Sigma, USA) supplemented with 
10% FBS (Sigma, USA), 2 mM L-glutamine, and 
40 mg/ml gentamycin at 37 °С in humidified atmo-
sphere with 5% СО2.
Cytotoxic/cytostatic activity of metformin hy-
drochloride (Sigma, USA) was assessed by IC50 as the 
concentration of the agent, which causes a 50% de-
crease in the number of living cells in relation to control 
due to its cytotoxic and/or cytostatic action, which was 
calculated using an appropriate mathematical model.
For this, C6 glioma cells or LLC cells were placed 
in wells of 96-well plates at a density of 1•104 cells/well, 
incubated overnight, then the medium was replaced 
by fresh medium with addition of metformin, and in-
cubation continued for 1 day.
Each concentration of the agent was investigated 
in repeat. Control cells were incubated under the same 
conditions without the addition of metformin.
The number of living cells was evaluated using 
sulforhodamine B (Sigma, USA) [16].
The nature of the dependence of the cytotoxic/
cytostatic action of metformin on LLC cells was ana-
lyzed using a mathematical model (1) that takes into 
account the existence of two subpopulations of tumor 
cells with varying sensitivity to the action of the drug:
N = A1 · exp(–C/t1) + A2 · exp(–C/t2), (1)
where N — number of viable cells (%), C — metfor-
min concentrations (mM), A1 and A2 — portion of LLC 
cells with different sensitivity to metformin action, 
t1 and t2 — parameters that characterize the sensitiv-
ity of cancer cells to metformin action (the lower the 
value of this parameter the higher sensitivity of the 
cells to metformin cytotoxicity).
The relationship between the number of viable 
C6 glioma cells and metformin concentrations was 
described by the following mathematical model (taking 
into account the existence of two subpopulations with 
different sensitivity to metformin action):
N1 = A1 – b1 · C, (2)
N2 = A2 – b2 · C (for C < 9.5 mM), (3)
where N1 and N2 — the portion of viable cells of the 
first and second subpopulations; A1 and A2 — the 
portion of resistant and sensitive respectively sub-
populations in glioma C6 cells; b1 and b2 — parameters 
characterizing the sensitivity of cancer cells of each 
subpopulation to metformin action (the higher the 
value of this parameter the higher sensitivity of cells 
to metformin cytotoxicity).
Parameters of mathematical models (1)–(3) were 
determined from their best approximation to the cor-
responding experimental data using nonlinear regres-
sion analysis.
Metformin doses and administration mode. 
Transplantation of LLC cells was performed intra-
muscularly (1•106 cells per mouse in 0.1 ml of Hanks’ 
solution).
After transplantation, the mice were randomized 
by weight and distributed into 3 groups: 1) mice ad-
ministered with metformin at a total dose of 150 mg/kg 
(Dmin, n = 8); 2) mice administered with metformin 
at a total dose of 300 mg/kg (Dmax, n = 9) and 3) mice 
administered with water (control, n = 9) according 
to the same scheme and in the same volume. Metfor-
min solution was prepared ex tempore on water and 
administered orally in a volume of 0.5 ml, daily, 5 times 
a week, for three weeks. In total 15 administrations 
were made.
Transplantation of С6 glioma cells was performed 
under total anesthesia via intracerebral inoculation 
of 0.6•106 cells per rat in 0.05 ml of physiologic solu-
tion in a left parietal area (anterior horn of left lateral 
ventricle).
After transplantation, the rats were randomized 
by weight and distributed into 3 groups: rats adminis-
tered with metformin at a total dose of 2.6 g/kg (Dmin, 
n = 7); rats administered with metformin at a total 
dose of 5.2 g/kg (Dmax, n = 7), and rats administered 
with water (control, n = 7) according to the same 
scheme and in the same volume. Metformin was used 
at doses close to the most tolerable: the daily dose 
of the drug was 200 and 400 mg/kg/day, respectively. 
According to [17], the first dose in the case of suffi-
ciently long application does not cause significant toxic 
manifestations, the second one is lower than the dose 
(600 mg/kg/rat), which causes minimal metabolic 
effects in rats, in particular, increased serum lactate 
and beta-hydroxybutyric acid and decreased serum 
bicarbonate and urine pH.
The drug was administered orally in 3 ml of water 
daily from the day following the tumor transplantation. 
In total 13 administrations were made.
Evaluation of the effectiveness of the antitu-
mor action of metformin with respect to LLC was per-
formed by the indexes of the effect of the drug on the 
growth of the primary tumor, the number of pulmonary 
metastases and their volume in mice after the end 
of therapy while in C6 glioma bearing rats — by survival 
time (ST) of the animals.
The changes in survival time (CST) of rats served 
as an index of anticancer effect of the metformin cal-
culated by a formula:
CST (%) = 100 • (ST — STC)/STC, (4)
where ST and STС are survival time of rats from 
experimental and control groups, respectively.
Evaluation of antitumor and antimetastatic activ-
ity of the metformin was performed at day 23 after 
tumor transplantation. Primary tumor diameter was 
measured triply per week starting from the moment 
of development of palpable tumors. Tumor volume (V) 
was calculated by the formula:
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V = 0.52d3 (5)
where d — tumor diameter.
The number and volume of lung metastases was 
routinely analyzed using binocular microscope and 
millimeter scale.
Volume of metastases (V) was calculated by the 
formula:
V = ∑ 
π (di)3
ni • 6  (6)
where ni — number of metastases with the diam-
eter of di.
Statistical analysis of the data was performed 
by descriptive methods, linear and nonlinear regres-
sion analysis, Student’s t-test with the use of Microsoft 
Excel and Microcal Origin programs. The data are 
presented as M ± m.
RESULTS ANd dISCUSSION
Effect of metformin on LLC cells in vitro and 
in vivo. The obtained data on the influence of met-
formin on the survival of LLC cells in vitro showed 
a high level of their sensitivity to the action of the drug. 
Fig. 1 shows the dependence of survival of LLC cells 
on the concentration of metformin in the incubation 
medium. As can be seen from Fig. 1, the mathematical 
model properly described the changes in the number 
of living cells due to the action of metformin. The 
determined parameters of the mathematical model 
for metformin with respect to LLC cells are presented 
in Table 1.
Table 1. Mathematical model parameters of LLC sensitivity against met-
formin
Symbols Units Value(M ± m)
A1 % 10.0 ± 2.2
A2 % 92.0 ± 3.5
t1 mM ∞
t2 mM 2.9 ± 0.3
R2 0.99
IC50 mM 2.42 ± 0.34
The mathematical analysis showed the presence 
of two subpopulations of LLC cells, which differ signifi-
cantly in the sensitivity to cytotoxic action of metformin. 
Subpopulation of cells characterized by high metfor-
min sensitivity (sensitivity index t2 = 2.9 ± 0.3 mM) 
achieved more than 90% of the total number of living 
cells (Table 1, Fig.1), causing a sufficiently high overall 
sensitivity of LLC cells to metformin action, which was 
confirmed by a low IC50 (2.42 ± 0.34 mM). Despite the 
fact that the subpopulation of metformin-resistant cells 
was only about 10% of cells from the total number 
of living cells, it is characterized by absolute insensitiv-
ity to the action of metformin over a wide range of drug 
concentrations (parameter t1 = ∞).
Despite the relatively high sensitivity of LLC cells 
to metformin in vitro, no significant effect of metfor-
min on LLC growth and metastasis was found in vivo. 
As can be seen from Fig. 2, the volume of primary 
tumor in mice receiving metformin both at the dose 
of 150 and 300 mg/kg, did not statistically differ from 
that in the control animals throughout all period of tu-
mor development.
At the end of therapy with metformin (23rd day after 
tumor transplantation), no significant effect of the two 
doses was found regarding both the volume of the 
primary tumor and metastasis (Table 2). Moreover, 
the tendency to stimulate the growth of the primary 
tumor in mice, if metformin was administered at a dose 
of 150 mg/kg, and a tendency to increase the lung 
metastasis if mice treated with metformin at a dose 
of 300 mg/kg were registered.
0
100
200
300
400
500
600
10 13 15 17 20 23
Tu
m
or
 vo
lu
m
e,
 m
m
3   
Day after tumor cell inoculation
Control Dmin Dmax
Fig. 2. The effect of metformin on tumor growth in LLC bear-
ing mice
Table 2. The action of metformin on LLC growth and metastasis values
Group Tumor volume(mm3)
Number 
of metastases
Volume of metastases
(mm3)
Control 396.0 ± 52.8 15.9 ± 4.7 22.3 ± 7.8
Metformin (Dmin) 495.3 ± 44.1 19.1 ± 5.2 29.6 ± 8.5
Metformin (Dmax) 327.8 ± 47.4 21.9 ± 6.3 53.0 ± 22.5
Effect of metformin on C6 glioma cells in vitro 
and in vivo. The study of the cytotoxic/cytostatic 
action of metformin in relation to C6 glioma cells 
revealed that these cells consist of two subpopula-
tions substantially differing in sensitivity to metformin 
cytotoxicity (Table 3, Fig. 3). As can be seen from 
Table 3, cell subpopulation with extremely low sensitiv-
ity to metformin action dominated among C6 glioma 
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Fig. 1. LLC cell survival as a function of metformin concentra-
tion in culture medium. Symbol — experimental data; line — 
model approximation obtained from the best fit of mathematical 
model (1) to experimental data
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cells. The metformin-resistant subpopulation was 
about 72% of all living cells, while metformin-sensitive 
cells composed only about 28% of their total number. 
Accordingly, IC50 for metformin-resistant subpopula-
tion was almost 16 times higher (p < 0.05) than that 
for metformin-sensitive subpopulation.
Table 3. Mathematical model parameters of glioma C6 cell sensitivity 
against metformin
Symbols Units Value(M ± m)
A1 % 72.3 ± 1.4
b1 %/mM 0.43 ± 0.005
IC50 (1) mM 84.1 ± 2.4
A2 % 30.8 ± 2.3
b2 %/mM 2.87 ± 0.4
IC50 (2) mM 5.37 ± 0.45
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Fig. 3. Glioma cell survival as a function of metformin concen-
tration in culture medium. Symbol — experimental data; line — 
model approximation obtained from the best fit of mathematical 
model (2, 3) to experimental data
Despite the predominance of metformin-resistant 
glomerular C6 cells in cell subpopulations in vitro, this 
drug exhibited a significant anti-glioma effect in in vivo 
experiments. Anti-glioma action of metformin was 
confirmed by a significant increase of the ST in rats 
with transplanted tumors, at least in the maximum 
dose being studied (Table 4, Fig. 4). In particulars, 
the average ST of rats treated with metformin at a total 
dose of 2.6 g/kg, did not differ significantly from that 
in the control. Instead, the average ST of rats treated 
with metformin with twice higher dose, 5.2 g/kg, was 
by 23% (p < 0.05) higher than the corresponding index 
of control animals.
Table 4. The action of metformin on ST of rats with glioma C6
Group ST, days
Control 13,1
Metformin (Dmin) 15,7
Metformin (Dmax) 16,1*
Notes: *p < 0.05 as compared to control.
So, the results of this study showed that, as in the 
case of LLC, and in the case of C6 glioma, the tumor 
cell population was heterogeneous and consisted 
of metformin-resistant and metformin-sensitive sub-
populations, and tumor cell susceptibility in vitro did 
not correlate with their sensitivity to the action of this 
agent in vivo. In C6 glioma cells cultured in vitro there 
was a large predominance of metformin-resistant 
subpopulation, which by 2.5 times exceeded metfor-
min-sensitive subpopulation. However, despite such 
dominance of the metformin-resistant cell subpopula-
tion in vitro, metformin exhibited in vivo a pronounced 
anti-glioma effect, which was manifested by statisti-
cally significant prolongation of the lifetime of tumor-
bearing rats.
In contrast, in the case of LLC, under in vitro con-
ditions, the metformin-sensitive cell subpopulation 
was almost an order of magnitude larger than such 
a metformin-resistant subpopulation, which, however, 
did not lead to the expected antitumor effect of this 
drug in vivo. Moreover, even a certain trend was ob-
served in stimulating the growth and metastasis of this 
tumor type.
The revealed effects indicated a lack of correlation 
between in vitro cytotoxic activity of metformin and its 
antitumor efficacy in vivo for both types of tumor cells. 
Such a lack of correlation between the sensitivity of tu-
mor cells to the action of metformin in vitro and in vivo, 
both in LLC and C6 glioma, indicated a significant con-
tribution of tumor microenvironment to the realization 
of antitumor action of the drug in vivo.
It is known that the microenvironment of solid 
tumors is characterized by a shortage of nutrients 
and hypoxia, which is a consequence of metabolism, 
first of all, tumor cells. The specific features of tumor 
microenvironment, undoubtedly, affect the antitumor 
effectiveness of metformin. Indeed, there is evidence 
that hypoxia greatly enhances the antiproliferative and 
apoptotic action of metformin against MCF-7 breast 
cancer cells [22].
In the case of metformin, the tumor microenviron-
ment is also formed due to its ability to regulate the 
metabolism of not only tumors, but also many normal 
cells of the body. In particular, it is known that met-
formin stimulates the usage of glucose and oxidation 
of fatty acids by skeletal myocytes, stimulates the 
oxidation of fatty acids and reduces glucose produc-
tion in hepatocytes, and, as a result, reduces blood 
glucose levels [8, 18], which results in an even greater 
fall in glucose content in a tumor microenvironment. 
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Fig. 4. Survival curves of rats with intracerebral glioma С6 treated 
with metformin
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On this basis, acute glucose deficiency in tumor 
microenvironment and the sensitivity of tumor cells 
to such a deficiency may be one of the main causes 
of inversion of the cytotoxic activity of metformin 
in relation to LLC and C6 glioma in vitro and in vivo. 
LLC cells are quite resistant to glucose deficiency due 
to their ability to pass under these conditions to the 
G0/G1 phase [19], which is associated with a low 
antitumor activity of metformin against LLC in vivo. 
By contrast, C6 glioma cells possess a high glucose 
dependence [20], which is clearly associated with 
a significant anti-glioma effect of this drug. It is also 
possible that the ability of metformin to reduce the 
permeability of blood vessels and cerebral edema 
caused by glioma in rats contributes to its antiglioma 
action [21].
In conclusion, the data showing the lack of corre-
lation between the in vitro cytotoxic/cytostatic action 
of metformin and its in vivo antitumor activity indicate 
an important role of the tumor microenvironment 
in the realization of its antitumor activity. Given the 
anti-glycemic mechanism of action of metformin, 
it is clear that the glucose deficiency itself in the tumor 
microenvironment and the sensitivity of tumor cells 
to such a deficiency determine the effectiveness of its 
antitumor activity against LLC and C6 glioma in vivo.
REFERENCES
1. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Met-
formin and reduced risk of cancer in diabetic patients. BMJ 
2005; 330: 1304–5.
2. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro 
metformin anti-neoplastic activity in epithelial ovarian cancer. 
Gynecol Oncol 2008; 110: 246–50.
3. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marja-
novic M, et al. In vitro and in vivo anti-melanoma action 
of metformin. Eur J Pharmacol 2011; 668: 373–82.
4. Luo Q, Hu D, Hu S, et al. In vitro and in vivo anti-
tumor effect of metformin as a novel therapeutic agent 
in human oral squamous cell carcinoma. BMC Cancer 2012; 
12: 517 (http://www.biomedcentral.com/1471-2407/12/517).
5. Sesen J, Dahan P, Scotland SJ, et al. Metformin 
ihibits growth of human glioblastoma cells and enhances 
therapeutic response. PLoS One 2015; 10: e0123721. 
DOI:10.1371/journal.pone.0123721.
6. Yu Z, Zhao G, Xie G, et al. Metformin and temozolo-
mide act synergistically to inhibit growth of glioma cells 
and glioma stem cells in vitro and in vivo. Oncotarget 2015; 
6: 32930–43.
7. Efremov RG, Baradaran R, Sazanov LA. The architecture 
of respiratory complex I. Nature 2010; 465: 441–5.
8. Zhou G, Myers R, Li Y, et al. Role of AMP-activated 
protein kinase in mechanism of metformin action. J Clin Invest 
2001; 108: 1167–74.
9. Zakikhani M, Dowling R, Fantus IG, et al. Metformin 
is an AMP kinase-dependent growth inhibitor for breast cancer 
cells. Cancer Res 2006; 66: 10269–73.
10. Owen MR, Doran E, Halestrap AP. Evidence that 
metformin exerts its anti-diabetic effects through inhibition 
of complex 1 of the mitochondrial respiratory chain. Biochem 
J 2000; 348: 607–14.
11. Song CW, Lee H, Dings RP, et al. Metformin kills and 
radiosensitizes cancer cells and preferentially kills cancer stem 
cells. Sci Rep 2012; 2: 362. doi: 10.1038/srep00362.
12. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, 
independent of AMPK, induces mTOR inhibition and cell-
cycle arrest through REDD1. Cancer Res 2011; 71: 4366–72.
13. Liu X, Chhipa RR, Pooya S, et al. Discrete mechanisms 
of mTOR and cell cycle regulation by AMPK agonists indepen-
dent of AMPK. Proc Natl Acad Sci USA 2014; 111: E435–44.
14. Hatoum D, McGowan ЕM. Recent advances in the 
use of metformin: can treating diabetes prevent breast can-
cer? BioMed Res Int 2015; 2015: Article ID 548436. 13 p. 
(http://dx.doi.org/10.1155/2015/548436).
15. Camacho L, Dasgupta A, Jiralerspong S. Metformin 
in breast cancer — an evolving mystery. Breast Cancer Res 
2015; 17: 88. DOI 10.1186/s13058-015-0598-8.
16. Vichai V, Kirtikara K. Sulforhodamine B colorimetric 
assay for cytoxicity screening. Nature Protocol 2006; 1: 1112–6.
17. Quaile MP, Melich DH, Jordan HL, et al. Toxicity and 
toxicokinetics of metformin in rats. Toxicol Appl Pharmacol 
2010; 243: 340–7.
18. Huang NL, Chiang SH, Hsueh CH, et al. Metformin 
inhibits TNF-alpha-induced IkappaB kinase phosphorylation, 
IkappaB-alpha degradation and IL-6 production in endothe-
lial cells through PI3K-dependent AMPK phosphorylation. 
Int J Cardiol 2009; 134: 169–75.
19. Pyaskovskaya ON, Kolesnik DL, Kolobov AV, et al. 
Analysis of growth kinetics and proliferative heterogeneity 
of Lewis lung carcinoma cells growing as unfed culture. Exp 
Oncol 2008; 30: 269–75.
20. Seyfried TN, Sanderson TM, El-Abbadi MM, et al. 
Role of glucose and ketone bodies in the metabolic control 
of experimental brain cancer. Br J Cancer 2003; 89: 1375–82.
21. Zhao B, Wang X, Zheng J et al. Effects of metformin 
treatment on glioma-induced brain edema. Am J Transl Res 
2016; 8: 3351–63.
22. Safari Z, Safaralizadeh R, Seyedzadeh MH, et al. The In-
duction of metformin inhibitory effects on tumor cell growth in hy-
poxic condition. Iran J Allergy Asthma Immunol 2015; 14: 605–14.
Copyright © Experimental Oncology, 2017
